After a hydroquinone course: what a melasma maintenance conversation needs

Improvement does not erase the underlying condition

AAD explains that melasma can persist and that treatment may need to address triggers as well as visible pigment. A lighter appearance after treatment does not necessarily mean the tendency to recur has disappeared. Recurrence also does not automatically prove that the first treatment was ineffective or that the person used it incorrectly.

At follow-up, ask the dermatologist to describe the current situation: what improved, what remains, and what factors still matter. That gives the next phase a clearer purpose than simply trying to preserve the best photograph. The aim may be reducing recurrence, avoiding unnecessary exposure to a medicine, improving tolerability, or reassessing a diagnosis that remains uncertain.

If a new spot looks different from the established melasma pattern, it deserves its own assessment. Do not treat every later change as a recurrence because one condition was diagnosed previously. Our concern guide keeps that distinction visible.

A medicine’s label can separate treatment from maintenance

TRI-LUMA is one useful example. Its prescribing information describes short-term treatment of moderate-to-severe facial melasma and explicitly does not indicate the product for maintenance treatment. It also notes that melasma commonly recurs after discontinuation. Both statements belong in the conversation, rather than selecting only the one that supports continued purchasing.

The TRI-LUMA review explains the exact combination and evidence boundaries. That product’s label is not a universal schedule for other hydroquinone preparations. A compounded formula may have different ingredients and instructions, which the prescriber should explain rather than borrowing an approved product’s treatment plan.

FDA’s compounding guidance adds another distinction: a compounded medicine has not undergone FDA premarket approval of the finished preparation. An individualized prescription may still be considered by a clinician, but the regulatory status should not disappear once the discussion moves from starting treatment to renewing it.

Decide what information the review needs

Bring the product name, active ingredients, actual directions, and when treatment began. Include any changes in the formula or prescribing instructions. If you missed applications or found the routine difficult, say so plainly; the clinician needs the actual course, not an ideal version reconstructed from the original plan.

Describe improvement and unwanted effects separately. Less pigment and more irritation can occur in the same overall experience. A financial investment in the cream should not force those observations into one positive verdict. The clinician can consider both when deciding what should happen next.

Photographs may support the discussion if requested, especially when taken under reasonably consistent conditions. They do not measure the treatment’s safety or replace examination. Share them through the care team’s approved channel and explain any relevant changes in makeup, lighting, or other skincare that could affect comparison.

Ask what the next phase is meant to accomplish

A useful question is not simply “What do I use instead?” Ask what the clinician wants to maintain and which parts of the current approach should remain. AAD describes a range of topical and procedural options for melasma, but that menu is not an instruction to try each one in sequence.

If another ingredient is proposed, ask why it fits your response and skin context. The azelaic acid comparison explains why an alternative has its own formulation, evidence, and tolerability questions. Switching an ingredient is not a guarantee of indefinite use without review.

Ask what should happen if pigment returns. Having a written contact and reassessment plan is different from having permission to restart an old prescription whenever the skin looks darker. Do not use leftover medicine beyond its instructions or adopt another person’s cycling schedule from an online discussion.

Keep protective care practical between visits

Sun protection remains relevant when visible pigmentation improves. AAD’s melasma guidance includes sunscreen, shade, and protective clothing, with additional discussion of iron-oxide-containing tinted sunscreen for visible-light protection. Our sunscreen guide helps translate those recommendations into label questions.

Tell the clinician if your current protection is uncomfortable, leaves a tint you cannot use, or does not fit your daily activities. A plan is easier to sustain when these barriers are addressed directly. The solution should preserve the intended protection rather than rely on using less product or assuming an indoor day always makes every protective measure irrelevant.

Also mention changes in medicines or hormonal circumstances to the appropriate clinician. Do not stop a medically necessary treatment because you suspect it is a melasma trigger. The question is how to coordinate care, not how to eliminate every possible influence independently.

Separate a renewal charge from a clinical decision

An automated order can continue on a schedule even when the treatment plan needs reassessment. Before the planned review point, confirm how upcoming shipments are handled and which team can pause or change them. A message about a skin reaction and a cancellation request may go through different channels.

CoreAge Rx’s Spot On offer advertises a starting monthly price and a provider-guided treatment approach. Its public description is not an individualized maintenance prescription. Ask for the exact intended treatment window and what follow-up or future charges apply to your proposed plan.

The billing guide helps compare a monthly equivalent, supplied quantity, and recurring order. Those details matter, but none should become the reason to extend treatment without medical review. Maintenance is a plan for the condition over time, not a commitment to keep buying the same cream forever.